id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2026-P-4021-0003,FDA,FDA-2026-P-4021,Final Response,Other,Letter(s),2026-06-15T04:00:00Z,2026,6,2026-06-15T04:00:00Z,,2026-06-15T22:19:21Z,,0,0,09000064b9328a95
FDA-2026-P-4021-0004,FDA,FDA-2026-P-4021,Relisting Notice Protamine Sulfate (Protamine Sulfate) IV Solution 50mg per mL,Supporting & Related Material,Background Material,2026-06-15T04:00:00Z,2026,6,,,2026-06-15T22:19:33Z,,0,0,09000064b9329751
FDA-2026-P-4021-0002,FDA,FDA-2026-P-4021,"Acknowledgement Letter from FDA DMB to Strides Pharma, Inc.",Other,Acknowledgement Letter/Receipt,2026-04-13T04:00:00Z,2026,4,2026-04-13T04:00:00Z,,2026-04-14T02:07:41Z,,0,0,09000064b927a270
FDA-2026-P-4021-0001,FDA,FDA-2026-P-4021,"Citizen Petition from Strides Pharma, Inc.",Other,Citizen Petition,2026-04-13T04:00:00Z,2026,4,2026-04-13T04:00:00Z,,2026-06-13T01:45:39Z,,0,0,09000064b927a26e